An additional bispecific, humanized IgG1 antibody that's underneath investigation is zenocutuzumab (MCLA-128), which acts via two unbiased mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by means of ADCC. MCLA-128 capabilities by means of a ‘dock and block’ mechanism whereby a person arm of your antibody https://www.directivepublications.org/journal-of-clinical-breast-cancer/